In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Dermata Therapeutics (DRMA – Research Report), with a price target of $4.00. The company’s shares opened today at $0.74.
Vendetti covers the Healthcare sector, focusing on stocks such as Aethlon Medical, ReShape Lifesciences, and Nephros. According to TipRanks, Vendetti has an average return of 1.5% and a 36.15% success rate on recommended stocks.
Dermata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.95 and a one-year low of $0.44. Currently, Dermata Therapeutics has an average volume of 1.52M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermata Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the treatment of multiple medical and aesthetic skin conditions and diseases with high unmet needs.
Read More on DRMA:
- Brady Corporation Announces Earnings Conference Call
- Nokia Corporation: Repurchase of own shares on 19.08.2022
- MasterCraft Boat Holdings, Inc. to Webcast Fiscal Fourth Quarter and Full Year 2022 Earnings Conference Call Thursday, September 8, 2022
- The Biggest Reason Why Microstrategy is Down Today
- 2 Buy-Rated Dividend Stocks Yielding at Least 7% (With Solid Upside to Boot)
